Introduction.

Inflammation biomarkers play a crucial role in the diagnosis and monitoring of treatment in patients with COVID-19. This disease triggers an unusual inflammatory response that worsens the patient's condition and leads to severe complications. Since 2020, convalescent plasma therapy has been used as a therapeutic option for patients with COVID-19. The main advantage of this treatment is the transfer of specific antibodies against the SARS-CoV-2 virus. These antibodies neutralize the virus and reduce the viral load in the body, helping to lessen the severity of the disease and accelerate the patient’s recovery

Objective.

The study evaluated the effect of convalescent plasma treatment on patients with COVID-19 at Cotahuma Municipal Hospital in 2020. The impact on levels of AST, ALT, LDH, CRP, and white blood cell count was analyzed as biomarkers of inflammation.

Materials and methods.

All patients with COVID-19 underwent analysis to assess the severity of their condition and their response to treatment. Blood levels of biomarkers considered predictors of inflammation or tissue damage were measured using quantitative kinetic methods, with appropriate external and internal quality control.

Results.

Significant differences were observed in the AST and ALT enzymes between the treatment groups. There was a decrease in leukocyte count and the LDH enzyme following the treatments. Regarding C-reactive protein, significant differences were noted after both treatments.

Conclusion.

A significant difference in CRP was found between convalescent plasma and other COVID-19 treatments. Despite variability in the volumes of plasma administered, plasma treatment was observed to reduce biomarkers in patients with moderate to critical health status, suggesting potential benefit. The comparison was made to highlight the advantages of convalescent plasma.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )